- Home
- EIM vs RIGL Comparison
EIM vs RIGL Comparison
Compare EIM & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIM | RIGL |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 564.7M |
| IPO Year | 2002 | 2000 |
Fundamental Metrics
Financial Performance| Metric | EIM | RIGL |
|---|---|---|
| Price | $9.67 | $42.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | 158.8K | ★ 296.1K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $31.66 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $9.48 | $24.84 |
| 52 Week High | $10.54 | $52.24 |
Technical Indicators
Market Signals| Indicator | EIM | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 61.35 |
| Support Level | $9.49 | $40.05 |
| Resistance Level | $10.00 | $44.42 |
| Average True Range (ATR) | 0.09 | 1.99 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 61.15 | 77.25 |
Price Performance
Historical ComparisonAbout EIM Eaton Vance Municipal Bond
Eaton Vance Municipal Bond Fund is a non-diversified closed-end management investment company. It consists of Municipal bond fund, California municipal bond fund, and New York municipal bond fund. The company's investment objective is to provide current income exempt from regular federal income tax, alternative minimum tax, and taxes in specified states. Its investment plan is to invest in higher quality bonds.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.